| |
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates.Register Now!
|
|
Today’s Big NewsJul 31, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Save up to $500 with Early Bird Rates. Register Now!
|
|
| By Annalee Armstrong We already know that Takeda is hoping to find a path to the FDA for epilepsy medicine soticlestat despite a phase 3 miss, but the Japanese pharma has now revealed that the clinical trial failure will cost to company just over $140 million. |
|
|
|
By James Waldron GSK has scrapped a phase 2 human papillomavirus vaccine from its pipeline after deciding the asset won’t have best-in-class potential. |
By Darren Incorvaia An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed cognitive decline by 18%. |
Sponsored by InMed Pharmaceuticals InMed Pharmaceuticals recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s disease. |
|
Maximize Your Brand Exposure From brand awareness to lead generation, our tailored marketing solutions help you achieve your objectives. Get noticed, start conversations, and drive demand with Fierce Biotech. Learn more now.
|
|
By Nick Paul Taylor Ideaya Biosciences is betting $400 million in biobucks that a bispecific antibody-drug conjugate can turbocharge the effect of its DNA damage repair molecules. The West Coast biotech dangled the cash to secure an option on a preclinical program in development at Biocytogen. |
By Nick Paul Taylor FibroGen is radically restructuring its business, laying off 75% of its U.S. staff and stopping investment in its lead candidate in response to the failure of two late-phase pancreatic cancer clinical trials. |
By James Waldron Tracon Pharmaceuticals has decided to wind down operations weeks after an injectable immune checkpoint inhibitor that was licensed from China flunked a pivotal trial in a rare cancer. |
By Darren Incorvaia The Swiss biotech presented preclinical results on its new Morphomer-antibody drug conjugate platform at the Alzheimer’s Association International Conference on July 29. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Kevin Dunleavy Six months after surviving a patent challenge involving its $3.2 million gene therapy, Sarepta faces a new lawsuit from another gene therapy developer claiming the approved treatment infringes active patents. Sanofi subsidiary Genzyme has filed a complaint in U.S. District Court in Delaware claiming that in producing groundbreaking Duchenne muscular dystrophy treatment Elevidys, Sarepta encroaches on two of its patents involving the manufacture of viral vectors. |
By Darren Incorvaia Digital technology company inFormed Consent has partnered with healthcare business development firm trifermed to launch a platform that will allow researchers to obtain informed consent from clinical trial participants remotely. |
By Kevin Dunleavy Three-year data from a study of early Alzheimer’s disease patients on Eisai and Biogen’s Leqembi showed that longer-term use provides continued benefits without additional safety concerns. |
By Heather Landi Flo Health, a reproductive and menstrual health app, secured $200 million in series C funding, boosting its valuation to more than $1 billion, the company announced Tuesday. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong highlights some of the most promising companies that made our prestigious Fierce 15 list back in 2014. |
|
|---|
|
|
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
